Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2018-99-116973

Published: 2018

Journal Articles

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Marie Scully, Paul Knoebl, MD, Karim Kentouche, Lawrence Rice, MD, Jerzy Windyga, MD, Reinhard Schneppenheim, Johanna A Kremer Hovinga, MD PhD, Michiko Kajiwara, Caterina Maggiore, Jennifer Doralt, Leah Martell, Bruce M. Ewenstein

Blood (2016) 128 (22): 135.

https://doi.org/10.1182/blood.V128.22.135.135

Published: 2016

Journal Articles

A Registry Study on Treatment of Patients with Acquired Protein C Deficiency with a Protein C Concentrate (Human)

Paul Knoebl, MD, Michael Sasse, MD, Maria Pia De Carolis, MD, Jacqueline A Dyck-Jones, PhD, Sandra Ehrle, MD, Maureen Finnerty, David Gelmont, MD, Leman Yel, MD, Mahmoud Loghman-Adham, MD, Doris Fischer, MD

Blood (2016) 128 (22): 3816.

https://doi.org/10.1182/blood.V128.22.3816.3816

Published: 2016

Journal Articles

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Wolfgang R. Sperr, MD, Susanne Herndlhofer, Karoline V Gleixner, MD, Michael Girschikofsky, MD, Ansgar Weltermann, MD, Sigrid Machherndl-Spandl, MD, Thamer Sliwa, MD, Rainer Poehnl, MD, Buxhofer-Ausch Veronika, MD, Karin Strecker, MD, Paul Knoebl, MD, Ulrich Jaeger, Klaus Geissler, MD, Michael Kundi, MD, Peter Valent, MD

Blood (2016) 128 (22): 2797.

https://doi.org/10.1182/blood.V128.22.2797.2797

Published: 2016

Journal Articles

Treatment Of Infection-Associated Purpura Fulminans With Protein C Zymogen Is Associated With a High Survival Rate

Paul Knoebl, MD, Peter Schellongowski, MD, Thomas Staudinger, MD, Wolfgang R. Sperr, MD, Christian Scheibenpflug, MD

Blood (2013) 122 (21): 3606.

https://doi.org/10.1182/blood.V122.21.3606.3606

Published: 2013

Journal Articles

Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results

Marilyn J. Manco-Johnson, MD, Paul Knoebl, MD, Amy D. Shapiro, MD, Maureen Finnerty, RN, MS, Leman Yel, MD, David Gelmont, MD

Blood (2013) 122 (21): 1146.

https://doi.org/10.1182/blood.V122.21.1146.1146

Published: 2013

Journal Articles

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

Andreas Tiede, MD, PhD, Jan-Malte Blumtritt, Robert Klamroth, MD, PhD, Saskia Gottstein, MD, Katharina Holstein, MD, Jürgen Heinz, MD, Rüdiger E. Scharf, MD, PhD, Angela Huth-Kühne, MD, PhD, Joachim F. Schenk, MD, PhD, Richard Greil, MD, Wolfgang A. Miesbach, MD, PhD, Ralf Ulrich Trappe, MD, PhD, Ute Scholz, MD, Daniela Manner, MD, Peter Neumeister, MD, Charis von Auer-Wegener, MD, Ulrich Kalus, MD, Klaus Leimkühler, MD, Paul Knoebl, MD

Blood (2013) 122 (21): 205.

https://doi.org/10.1182/blood.V122.21.205.205

Published: 2013

Journal Articles

International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome

Magnus Mansouri Taleghani, Yoshihiro Fujimura, MD, PhD, James N. George, MD, Ingrid Hrachovinova, PhD, Paul Knoebl, MD, Bernhard Lämmle, MD, Petter Quist-Paulsen, MD, PhD, Reinhard Schneppenheim, MD, PhD, Johanna A. Kremer Hovinga Strebel, MD

Blood (2012) 120 (21): 4654.

https://doi.org/10.1182/blood.V120.21.4654.4654

Published: 2012

Journal Articles

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

Wolfgang R. Sperr, MD, Otto Zach, PhD, Iris Poell, Michael Kundi, MD, Susanne Herndlhofer, Ulrich Jaeger, MD, Paul Knoebl, MD, Ansgar Weltermann, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2504.

https://doi.org/10.1182/blood.V118.21.2504.2504

Published: 2011

Journal Articles

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

Petra Jilma-Stohlawetz, MD, Paul Knoebl, MD, Ingrid Pabinger, MD, James Gilbert, MD, Robert G. Schaub, PhD, Bernd Jilma, MD

Blood (2011) 118 (21): 3377.

https://doi.org/10.1182/blood.V118.21.3377.3377

Published: 2011

Journal Articles

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Petra Paulinska, MD, Bernd Jilma, MD, Christa Firbas, MD, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 3374.

https://doi.org/10.1182/blood.V112.11.3374.3374

Published: 2008

Journal Articles

Proof of Concept for the Anti Von Willebrand Factor Aptamer in Patients with Relapsing Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Ji lma, MD, Petra Jilma, MD, Petra Paulinska, MD, James C. Gilbert, MD, Renta Hutabarat, PhD, Trish Wagner, Paul Knoebl, MD

Blood (2008) 112 (11): 2290.

https://doi.org/10.1182/blood.V112.11.2290.2290

Published: 2008

Journal Articles

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Chri sta Firbas, MD, Bernd Jilma, MD, Patricia G Wagner, Renta Hutabarat, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 2298.

https://doi.org/10.1182/blood.V112.11.2298.2298

Published: 2008

Journal Articles

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Jilma, MD, Florian B. Mayr, MD, Paul Knoebl, MD, Alexander O. Spiel, MD, Patricia G. Merlino, Robert Schaub, PhD, James C. Gilbert, MD

Blood (2007) 110 (11): 279.

https://doi.org/10.1182/blood.V110.11.279.279

Published: 2007

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

The European Acquired Haemophilia (EACH) Registry.

Francesco Baudo, MD, Jef Arnout, MD, Peter Collins, MD, Angela Huth-Kühne, MD, Hervé Levesque, MD, Paul Knoebl, MD, Pascual Marco, MD, Laszlo Nemes, MD, Lilian Tengborn

Blood (2005) 106 (11): 3205.

https://doi.org/10.1182/blood.V106.11.3205.3205

Published: 2005

NARROW

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

A Registry Study on Treatment of Patients with Acquired Protein C Deficiency with a Protein C Concentrate (Human)

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Treatment Of Infection-Associated Purpura Fulminans With Protein C Zymogen Is Associated With a High Survival Rate

Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome

Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy

Inhibition of Von Willebrand Factor (VWF) by ARC1779 Normalizes Von Willebrand Factor/FVIII Levels and Corrects Thrombocytopenia in VWD Type 2b Patients,

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Proof of Concept for the Anti Von Willebrand Factor Aptamer in Patients with Relapsing Thrombotic Thrombocytopenic Purpura (TTP).

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

The European Acquired Haemophilia (EACH) Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only